Loading clinical trials...

The Effect of Using Distractor Cards and Thermochromic Cards on Pain, Fear, Anxiety and Procedure Time in Children Receiving Inhaler Therapy | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGNA

The Effect of Using Distractor Cards and Thermochromic Cards on Pain, Fear, Anxiety and Procedure Time in Children Receiving Inhaler Therapy

NCT07371026•Muhammed Ata Nur GEÇER

View on ClinicalTrials.gov

Summary

THE EFFECT OF USİNG DİSTRACTOR CARDS AND THERMOCHROMİC CARDS ON PAİN, FEAR, ANXİETY AND PROCEDURE TİME İN CHİLDREN RECEİVİNG INHALER THERAPY. Respiratory illnesses in children are a leading cause of childhood morbidity and mortality worldwide. Organizations such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) report that millions of children are hospitalized each year due to respiratory illnesses (He, Wang, \& Zhang, 2025). A large proportion of these illnesses are caused by viral agents, and pathogens such as Respiratory Syncytial Virus (RSV), influenza, and rhinoviruses pose serious health threats to young children (Chen, Zhang, \& Li, 2024). This study will be one of the rare studies in pediatric nursing that examines the effectiveness of non-pharmacological interventions that can be applied during inhaler therapy in young age groups. The findings will contribute to nurses developing effective methods to reduce the negative emotions experienced by children during treatment. Furthermore, the first-ever use of thermochromic cards in this context in pediatric nursing will provide an innovative perspective on pediatric nursing practices. H0: Thermochromic cards and distraction cards used during inhaler therapy have no effect on pain, fear, anxiety levels, or processing time. Thermochromic cards used during inhaler therapy: H1: reduce the child's pain. H2: reduce the child's fear. H3: reduce the child's anxiety level. H4: shorten the child's processing time. Distraction cards used during inhaler therapy: H5: reduce the child's pain. H6: reduce the child's fear. H7: reduce the child's anxiety level. H8: shorten the child's processing time.

Eligibility

Age

3 - 6 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•The child must be between 4-6 years old,
•The child must be receiving inhaler treatment,
•The child must not have received IV or IM intervention before inhaler treatment,
•The child's oxygen saturation must be 95% or higher,
•The child's cognitive level and motor development must be appropriate for their age,
•The child and parents must be willing to participate in the study,
•The child and parents must be able to speak Turkish.

Exclusion Criteria

•The child must have a cognitive or mental problem,
•The child must have special needs in terms of hearing, vision and/or speech,
•The child must have a life-threatening condition,
•The child's oxygen saturation level must be below 95%,
•The child must not be routinely receiving inhaler treatment

Key Dates

Start Date

March 1, 2026

Primary Completion Date

March 1, 2027

Completion Date

March 1, 2027

Last Updated

January 30, 2026

Enrollment

ESTIMATED participants

Conditions

Pediatric Acute Upper Respiratory Tract InfectionPediatricPediatric Acute Respiratory Failure

Interventions

thermochromic card

OTHER

distraction card

OTHER

Contacts

Muhammed Ata Nur GEÇER, MsC, PhD (Candicate)

CONTACT

+905455258654 mangecer0@gmail.com

Transcutaneous pO₂ Monitoring in PICU

NCT07478380

Pediatric Critical Illness

View study

RECRUITINGPHASE1

Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies

NCT05011422

Pediatric Hematologic Malignancies

View study

RECRUITINGPHASE2/PHASE3

Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS

NCT05267821

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 30, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Effect of Using Distractor Cards and Thermochromic Cards on Pain, Fear, Anxiety and Procedure Time in Children Receiving Inhaler Therapy

Inclusion Criteria

Exclusion Criteria

Transcutaneous pO₂ Monitoring in PICU

Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies

Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS

COPM-Based Goal Setting Strategies in the PICU

Premedication in Children: a Clinical Trial Comparing Oral Ketamine and Oral Clonidine With Respect to Sedation Level and Opioid Consumption in Pediatrics Undergoing Elective Lower Abdominal Day-case Surgery.

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma